Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRD5A2 | P31213 | 3/20 | 0.64 |
| ▸ | AR | P10275 | 1/20 | 0.64 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8764686 | 1.00 | SRD5A2 (0.64) | SRD5A2ARSRD5A1 | |
| SCHEMBL9213222 | 0.92 | SRD5A2 (0.60) | SRD5A2ARSRD5A1 | |
| SCHEMBL9213209 | 0.92 | SRD5A2 (0.60) | SRD5A2ARSRD5A1 | |
| SCHEMBL9212370 | 0.91 | SRD5A2 (0.58) | SRD5A2ARSRD5A1 | |
| SCHEMBL9212359 | 0.91 | SRD5A2 (0.58) | SRD5A2ARSRD5A1 | |
| SCHEMBL9620153 | 0.90 | SRD5A2 (0.62) | SRD5A2ARSRD5A1 | |
| SCHEMBL9620150 | 0.90 | SRD5A2 (0.62) | SRD5A2ARSRD5A1 | |
| SCHEMBL12384448 | 0.89 | SRD5A2 (0.65) | SRD5A2ARSRD5A1 | |
| SCHEMBL12423996 | 0.89 | SRD5A2 (0.65) | SRD5A2ARSRD5A1 | |
| SCHEMBL9309301 | 0.87 | SRD5A2 (0.58) | SRD5A2ARSRD5A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0576603-A1 | PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF PROSTATIC HYPERPLASIA, CONTAINING A 5 ALPHA-REDUCTASE INHIBITOR AND AN ANTIANDROGEN | MERCK & CO. INC. (US) | 1994-01-05 | — | — | EP | disclosed |
| EP-0285383-A2 | Treatment of prostatic carcinoma with 17beta-n-monosubstituted-carbamoyl-4-aza-5alpha-androst-1-en-3-ones | MERCK & CO. INC. (US) | 1988-10-05 | — | — | EP | disclosed |
| EP-0285382-A2 | Treatment of androgenic alopecia with 17beta-n-monosubstituted-carbamoyl-4-aza-5alpha-androst-1-en-3-ones | MERCK & CO. INC. (US) | 1988-10-05 | — | — | EP | disclosed |